Adding Keytruda to Xtandi did not improve survival in patients with metastatic castration-resistant prostate cancer. The addition of Keytruda ...

The patient samples showed that ecDNA can be a truncal driver of oesophageal cancer.   That had been hidden because, unlike chromosomal DNA, ecDNA isn’t ...

Patients with colorectal cancer saw improved progression-free survival with the drug combination of Lumakras plus Vectibix. Treatment with combinations ...

Platinum-based chemotherapy, given before chemoradiation, improved outcomes for patients with advanced cervical cancer. Patients with locally advanced ...

Padcev plus Keytruda outperformed chemotherapy when it came to overall survival and progression-free survival in frontline advanced bladder cancer ...

Tivdak (tisotumab vedotin-tftv) reduced the risk for death by 30% compared with chemotherapy as second- or third-line therapy in patients with recurrent or ...

Adding Opdivo to standard of care chemotherapy improved survival in certain patients with bladder cancer. Compared with chemotherapy alone, patients with ...

Welireg improved outcomes for certain patients with clear cell renal cell carcinoma, research showed. Patients with preterated advanced clear cell renal ...

Tagrisso plus chemotherapy improved progression risk in EGFR-positive lung cancer. Patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated ...

Retevmo improved progression-free survival, compared with chemotherapy with or without Keytruda in patients with RET-fusion positive non-small cell lung ...

Treatment with Retevmo improved progression-free survival and overall response rate in patients with advanced RET-mutant medullary thyroid cancer who were ...

The treatment combination of Rybrevant plus chemotherapy offers better progression-free survival for patients with advanced EGFR exon 20 insertion-positive ...